Àá½Ã¸¸ ±â´Ù·Á ÁÖ¼¼¿ä. ·ÎµùÁßÀÔ´Ï´Ù.

¼º¹®»óºÎ¾ÏÀÇ ±ÙÄ¡Àû ¹æ»ç¼±Ä¡·á Curative Radiotherapy of Supraglottic Cancer

´ëÇѹæ»ç¼±Á¾¾çÇÐȸÁö 1998³â 16±Ç 2È£ p.139 ~ 145
À̵¿¼±, ½ÉÇö¼®,
¼Ò¼Ó »ó¼¼Á¤º¸
À̵¿¼± (  ) 
°æºÏ´ëÇб³ Áø´Ü¹æ»ç¼±°ú

½ÉÇö¼® (  ) 
°æ»ó´ëÇб³ ÀÇ°ú´ëÇÐ Ä¡·á¹æ»ç¼±°úÇб³½Ç,

Abstract

¸ñ Àû : ¼º¹®»óºÎ¾Ï¿¡¼­ ±ÙÄ¡Àû ¹æ»ç¼±Ä¡·áÀÇ È¿À²¼ºÀ» ¾Ë¾Æº¸°íÀÚ ÇÏ¿´´Ù.

´ë»ó ¹× ¹æ¹ý : ¼º¹®»óºÎ ÆíÆò»óÇǼ¼Æ÷¾ÏÀ¸·Î È®ÁøµÇ¾î 1990³â 3¿ùºÎÅÍ 1994³â 12¿ù±îÁö °æ»ó´ëÇб³º´¿ø Ä¡·á¹æ»ç¼±°ú¿¡¼­ ±ÙÄ¡Àû ¹æ»ç¼±Ä¡·á¸¦ ½ÃÇàÇÑ 21¿¹¸¦ ´ë»óÀ¸·Î ºÐ¼®À» ½ÃÇàÇÏ¿´´Ù. ȯÀÚÀÇ ¿¬·É ºÐÆ÷´Â 52¼¼ºÎÅÍ 75¼¼·Î Áß¾Ó°ªÀº 62¼¼ À̾ú´Ù. ³²ÀÚ°¡ 19¿¹À̾ú°í
¿©ÀÚ´Â 2¿¹À̾ú´Ù. AJCC TNM º´±â¿¡ µû¸¥ ȯÀÚÀÇ ºÐÆ÷´Â º´±â IÀÌ 4¿¹, º´±â II°¡ 7¿¹, º´±â IIIÀÌ 3¿¹, º´±â IV°¡ 7¿¹À̾ú´Ù. ÃßÀûÁ¶»ç±â°£ÀÇ Áß¾Ó°ªÀº 36°³¿ùÀ̾ú°í 95%°¡ ÃßÀûÀÌ °¡´ÉÇÏ¿´´Ù.

°á °ú : ¼º¹®»óºÎ¾Ï ȯÀÚ 21¿¹ÀÇ Àüü 5³â »ýÁ¸À²Àº 39.3%À̾ú´Ù. º´±â¿¡ µû¸¥ 5³â »ýÁ¸À²Àº º´±â IÀÌ 75.0%, º´±â II°¡ 42.9%, º´±â IIIÀÌ 33.3%, º´±â IVÀÌ 28.6%À̾ú´Ù. Àüü 5³â ±¹¼ÒÁ¦¾îÀ²Àº 52.0%À̾ú°í, º´±â¿¡ µû¸¥ ±¹¼ÒÁ¦¾îÀ²Àº º´±â I°¡ 75.0%, º´±â IIÀÌ 57.1%,
º´±â IIIÀÌ 66.7%, º´±â IV°¡ 28.6%À̾ú´Ù. ¼º¹®»óºÎ¾ÏÀÇ Ä¡·á ÈÄ 3¿¹ÀÇ È¯ÀÚ¿¡¼­ ÀÌÂ÷ ¿ø¹ßÁ¾¾çÀÌ ½Äµµ¿¡ ¹ß»ýÇÏ¿´°í, Áø´Ü ÈÄ °¢±â 5°³¿ù, 6°³¿ù, 6°³¿ù¿¡ »ç¸ÁÇÏ¿´´Ù.

°á ·Ð : º´±â I, IIÀÇ Á¶±â ¼º¹®»óºÎ¾ÏÀÇ Ä¡·á½Ã ¿ì¼± ±ÙÄ¡Àû ¹æ»ç¼±Ä¡·á¸¦ ½ÃÇàÇÏ°í, Ä¡·á½ÇÆнà ±¸Á¦¼ö¼úÀ» ½ÃÇàÇÏ´Â °ÍÀÌ ³ôÀº ±¹¼ÒÁ¦¾îÀ²°ú ¼º´ë º¸Á¸À²À» ±â´ëÇÒ ¼ö ÀÖ´Â È¿°úÀûÀÎ Ä¡·á ¹æ¹ýÀ̶ó°í ÆǴܵȴÙ. ÁøÇàµÈ º´±â¿¡¼­´Â ¼ö¼úÀÌ °¡´ÉÇÑ °æ¿ì ±ÙÄ¡Àû ¼ö¼ú°ú
¹æ»ç¼±¿ä¹ýÀ» º´ÇàÇÏ°í ¼ö¼úÀÌ ºÒ°¡´ÉÇÑ °æ¿ì¿¡¸¸ ±ÙÄ¡Àû ¹æ»ç¼±Ä¡·á¸¦ ½ÃÇàÇÏ´Â °ÍÀÌ ±ÇÀåµÈ´Ù

Purpose : The purpose of this study was to evaluate the efficacy of curative radiotherapy in the management of supraglottic cancer.

Materials and Methods : Twenty-one patients with squamous cell carcinoma of the supraglottis were treated with radiotherapy at Gyeongsang National University Hospital between 1990 and 1994. Median follow-up period was 36 months and 95% were
observed for at least 2 years.

Results : Actuarial survival rate at 5 years was 39.3% for 21 patients. The 5-year actuarial survival rate was 75.0% in Stage I, 42.9% in Stage II, 33.3% in Stage III, and 28.6% in Stage IV(p=0.54). The 5-year local control rate was 52.0% for 21 patients. The 5-year local control rate was 75.0% in Stage I, 57.1% in Stage II, 66.7% in Stage III, and 28.6% in Stage IV(p=0.33). Double primary cancer was developed in 3 patients and those were all esophageal cancers.

Conclusion : In early stage(Stage I and II) supraglottic cancer, curative radiotherapy would be a treatment of choice and surgery would be better to be reserved for salvage of radiotherapy failure. In advanced stage(Stage III and IV), radiotherapy
alone is inadequate for curative therapy and combination with surgery should be done in operable patients. This report emphasizes the importance of esophagoscopy and esophagogram at the follow-up of patients with supraglottic cancer.

Å°¿öµå

Supraglottic cancer; Radiotherapy

¿ø¹® ¹× ¸µÅ©¾Æ¿ô Á¤º¸

   

µîÀçÀú³Î Á¤º¸

KCI
KoreaMed
KAMS